Download PDF
Thromb Haemost 2011; 106(05): 987-989
DOI: 10.1160/TH11-05-0351
Letters to the Editor
Schattauer GmbH

Bleeding diathesis in patients with mast cell activation disease

Holger Seidel   *
1   Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
2   Current address: Institute of Hemostasis and Transfusion Medicine, University Clinic Düsseldorf, Düsseldorf, Germany
,
Gerhard J. Molderings   *
3   Institute of Human Genetics, University Hospital of Bonn, Bonn, Germany
,
Johannes Oldenburg
1   Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
,
Kirsten Meis
4   Evangelische Kliniken Bonn, Waldkrankenhaus, Bonn, Germany
,
Ulrich W. Kolck
4   Evangelische Kliniken Bonn, Waldkrankenhaus, Bonn, Germany
,
Jürgen Homann
4   Evangelische Kliniken Bonn, Waldkrankenhaus, Bonn, Germany
5   Current address: Gemeinschaftskrankenhaus Bonn, Bonn, Germany
,
Hans-Jörg Hertfelder   *
1   Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
› Author Affiliations
Further Information

Publication History

Received: 24 May 2011

Accepted after minor revision: 22 July 2011

Publication Date:
23 November 2017 (online)

Also available at
  PDF Download  Permissions and Reprints

* These authors contributed equally to the study


 

  • References

  • 1 Campbell Jr, EW, Hector D, Gossain V. Heparin activity in systemic mastocytosis. Ann Intern Med 1979; 90: 940-941.
    CrossrefPubMedGoogle Scholar
  • 2 Adler SN, Klein RA, Lyon DT. Bleeding after liver biopsy in a patient with systemic mastocytosis and malabsorption. J Clin Gastroenterol 1985; 7: 350-353.
    CrossrefPubMedGoogle Scholar
  • 3 Horan RF, Austen KF. Systemic mastocytosis: restrospective review of a decade´s clinical experience at the Brigham and Women´s Hospital. J Invest Dermatol 1991; 96 (Suppl.) 5S-14S.
    CrossrefPubMedGoogle Scholar
  • 4 Parker RI. Hematologic aspects of systemic mastocytosis. Mast Cell Disorders 2000; 14: 557-568.
    PubMedGoogle Scholar
  • 5 Puretic S, Milavec D. Clinical varieties of mastocytoses. Acta Med Croatica 2001; 55: 61-66.
    PubMedGoogle Scholar
  • 6 Koenig M, Morel J, Reynaud J. et al. An unusual cause of spontaneous bleeding in the intensive care unit - mastocytosis: a case report. Cases J 2008; 1: 100
    CrossrefPubMedGoogle Scholar
  • 7 Sucker C, Mansmann G, Steiner S. et al. Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis. Clin Appl Thromb Hemost 2008; 14: 360-364.
    CrossrefPubMedGoogle Scholar
  • 8 Steiner DR, Gonzalez NC, Wood JG. Mast cells mediate the microvascular inflammatory response to systemic hypoxia. J Appl Physiol 2003; 94: 325-334.
    CrossrefPubMedGoogle Scholar
  • 9 Stevens RL, Fox CC, Lichtenstein LM. et al. Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc Natl Acad Sci USA 1988; 85: 2284-2287.
    CrossrefPubMedGoogle Scholar
  • 10 Sillaber C, Baghestanian M, Bevec D. et al. The mast cell as site of tissue type plasminogen activator production and fibrinolysis. J Immunol 1999; 62: 1032-1041.
    PubMedGoogle Scholar
  • 11 Strbian D, Karjalainen-Lindsberg ML, Kovanen PT. et al. Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 2007; 116: 411-418.
    CrossrefPubMedGoogle Scholar
  • 12 Hertfelder HJ, Popov-Cenic S. Short-time centrifugation at high centrifugal forces in plasma preparation for tPA activity determination. Thromb Res 1990; 59: 417-420.
    CrossrefPubMedGoogle Scholar
  • 13 Molderings GJ, Meis K, Kolck UW. et al. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 2010; 62: 721-727.
    CrossrefPubMedGoogle Scholar